AC-262,356

AC-262,356

AC-262,356
Systematic (IUPAC) name
4-(3-Hydroxy-8-aza-bicyclo[3.2.1]octyl)-naphthalene-1-carbonitrile
Clinical data
Legal status
?
Identifiers
ATC code ?
PubChem
Chemical data
Formula C18H18N2O 
Mol. mass 278.348 g/mol
 YesY   

AC-262,356 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.[1]

References

  1. ^ Piu, F; Gardell, LR; Son, T; Schlienger, N; Lund, BW; Schiffer, HH; Vanover, KE; Davis, RE; Olsson, R; Bradley, SR (2008). "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". The Journal of Steroid Biochemistry and Molecular Biology 109 (1–2): 129–37.